Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

Jason Luke, MD
Published: Friday, Oct 27, 2017



Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

A combination that is of a lot of interest is a PD-1 antibody and an oncolytic virus, states Luke. There are drugs that are approved for each as a monotherapy, but the combination of pembrolizumab and T-VEC has the potential to be promising.

T-VEC is a modified virus that is injected into melanoma tumors that are on the skin.  
SELECTED
LANGUAGE


Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

A combination that is of a lot of interest is a PD-1 antibody and an oncolytic virus, states Luke. There are drugs that are approved for each as a monotherapy, but the combination of pembrolizumab and T-VEC has the potential to be promising.

T-VEC is a modified virus that is injected into melanoma tumors that are on the skin.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x